Glucagon-like peptide-1 analogues for type 2 diabetes

BMJ

Volumn 342, Issue 7794, 2011, Pages 433-435

  Wilding, John P H ^a   Hardy, Kevin ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b St Helens Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE REACTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 79951962172     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d410     Document Type: Article

References (23)

1. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35. (Pubitemid 39441462)
2. Kendall DM, Riddle MC, Rosenstock J, Zhuang DL, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91. (Pubitemid 40616617)
3. Zinman B, Hoogwerf BJ, Garcia SD, Milton DR, Giaconia JM, Kim DD, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes - a randomized trial. Ann Intern Med 2007;146:477-85. (Pubitemid 351650556)
4. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100. (Pubitemid 40616618)
5. Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 2006;22:483-91. (Pubitemid 44774053)
6. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;8:419-28. (Pubitemid 44349234)
7. Klonoff DC, Buse JB, Nielsen LL, Guan XS, Bowlus CL, Holcombe JH, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86. (Pubitemid 351160260)
8. Heine RJ, van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - a randomized trial. Ann Intern Med 2005;143:559-69.
9. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67.
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
11. National Institute for Health and Clinical Excellence. Type 2 diabetes - newer agents (partial update of CG66). (Clinical guideline 87.) 2009. http://guidance.nice.org.uk/CG87.
12. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
13. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90.
14. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
15. Marre M, Shaw J, Brandle M, Bebakar WMW, Kamaruddin NA, Strand J, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26(3):268-78.
16. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
17. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
18. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
19. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3.
20. National Institute for Health and Clinical Excellence. Liraglutide for the treatment of type 2 diabetes mellitus. (Technology appraisal 203.) 2010. http://guidance.nice.org.uk/TA203.
21. Medicines and Healthcare Products Regulatory Agency. Drug safety update. Vol 2(8). MHRA, 2009. www.mhra.gov.uk/Publications/Safetyguidance/ DrugSafetyUpdate/CON041211.
22. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clinical Therapeutics 2009;31:1511-23.
23. Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007;23:609-22. (Pubitemid 46456909)